Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q1 2021 · 10-Q
Revenue$87.72M$87.72M+14.7% vs Q1 2020 Net Income$15.66M$15.66M+3,380.4% vs Q1 2020 EPS Diluted$0.41$0.41+4,000.0% vs Q1 2020 Gross Profit$55,598,000+42.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flow$20,570,000N/M Free Cash Flowderived$20,142,000N/M Margins · derivedGross margin63.4%+12.4 pt vs Q1 2020
Operating margin24.2%+17.5 pt vs Q1 2020
Net margin17.9%+17.3 pt vs Q1 2020
ended Mar 31, 2021 · filed May 6, 2021 · 36 d after period end